EDAP TMS SA Appoints Joshua H. Levine to Board

TL;DR

EDAP TMS SA adds Joshua H. Levine to its board, boosting medical device expertise.

AI Summary

EDAP TMS SA announced on January 10, 2025, the appointment of Joshua H. Levine to its Board of Directors. Levine brings extensive experience in the medical device industry to the company, which is a global leader in robotic energy-based therapies.

Why It Matters

The addition of a new director with relevant industry experience can signal strategic growth or improved governance for EDAP TMS SA.

Risk Assessment

Risk Level: low — This filing is a routine announcement of a board appointment and does not contain significant financial or operational risks.

Key Players & Entities

• EDAP TMS SA (company) — Company making the announcement
• Joshua H. Levine (person) — Newly appointed Board of Directors member
• January 10, 2025 (date) — Date of the announcement and appointment
• Nasdaq: EDAP (company) — Stock ticker for EDAP TMS SA

FAQ

Key Financial Figures

• $2 billion — apital in August 2011 for approximately $2 billion. From 2004 to 2010, Mr. Levine served a
• $1.2 billion — ohnson & Johnson (J&J) in June 2008 for $1.2 billion. His independent public company direct

Filing Documents

• f6k_011025.htm (6-K) — 15KB
• 0001171843-25-000154.txt ( ) — 16KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 10, 2025 EDAP TMS S.A. /s/ KEN MOBECK KEN MOBECK CHIEF FINANCIAL OFFICER EDAP Appoints Joshua H. Levine to Board of Directors AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors. "We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing on transformative, high growth business strategies within the medical technology sector. As EDAP continues to grow the market for its leading Focal One Ò robotic HIFU platform, Josh will help shape our strategic vision and execution as we expand our leadership in developing the most advanced HIFU technology applications for addressing multiple therapeutic areas." "I am very excited to join EDAP's Board of Directors, particularly at a time when the Focal One platform is clearly transforming the treatment paradigm within prostate cancer," said Josh Levine. "Over the last two years, EDAP has made significant progress in establishing Focal One as the dominant and most technologically advanced platform for delivering robotic HIFU. As a member of the Board of Directors, I look forward to working with EDAP's senior executives to help expand this exciting technology which clearly has the potential to transform treatment paradigms across a broad range of indications, including endometriosis and BPH." Mr. Levine is a strategic business leader with decades of diverse global board and executive management experience within the medical technology industry. He possesses a deep exp

Forward-Looking Statements

Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the "Securities Act") or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as "believe," "can," "contemplate," "could," "plan," "intend," "is designed to," "may," "might," "potential," "objective," "target," "project," "predict," "forecast," "ambition," "guideline," "should," "will," "estimate," "expect" and "anticipate," or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on

Forward-looking statements speak only as of the

Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.com Investor Contact John Fraunces LifeSci Advisors, LLC (917) 355-2395 jfraunces@lifesciadvisors.com

View Full Filing

View this 6-K filing on SEC EDGAR